233 related articles for article (PubMed ID: 35579976)
1. Circulating free testosterone and risk of aggressive prostate cancer: Prospective and Mendelian randomisation analyses in international consortia.
Watts EL; Perez-Cornago A; Fensom GK; Smith-Byrne K; Noor U; Andrews CD; Gunter MJ; Holmes MV; Martin RM; Tsilidis KK; Albanes D; Barricarte A; Bueno-de-Mesquita B; Chen C; Cohn BA; Dimou NL; Ferrucci L; Flicker L; Freedman ND; Giles GG; Giovannucci EL; Goodman GE; Haiman CA; Hankey GJ; Huang J; Huang WY; Hurwitz LM; Kaaks R; Knekt P; Kubo T; Langseth H; Laughlin G; Le Marchand L; Luostarinen T; MacInnis RJ; Mäenpää HO; Männistö S; Metter EJ; Mikami K; Mucci LA; Olsen AW; Ozasa K; Palli D; Penney KL; Platz EA; Rissanen H; Sawada N; Schenk JM; Stattin P; Tamakoshi A; Thysell E; Tsai CJ; Tsugane S; Vatten L; Weiderpass E; Weinstein SJ; Wilkens LR; Yeap BB; ; ; ; ; ; Allen NE; Key TJ; Travis RC
Int J Cancer; 2022 Oct; 151(7):1033-1046. PubMed ID: 35579976
[TBL] [Abstract][Full Text] [Related]
2. Circulating insulin-like growth factors and risks of overall, aggressive and early-onset prostate cancer: a collaborative analysis of 20 prospective studies and Mendelian randomization analysis.
Watts EL; Perez-Cornago A; Fensom GK; Smith-Byrne K; Noor U; Andrews CD; Gunter MJ; Holmes MV; Martin RM; Tsilidis KK; Albanes D; Barricarte A; Bueno-de-Mesquita HB; Cohn BA; Deschasaux-Tanguy M; Dimou NL; Ferrucci L; Flicker L; Freedman ND; Giles GG; Giovannucci EL; Haiman CA; Hankey GJ; Holly JMP; Huang J; Huang WY; Hurwitz LM; Kaaks R; Kubo T; Le Marchand L; MacInnis RJ; Männistö S; Metter EJ; Mikami K; Mucci LA; Olsen AW; Ozasa K; Palli D; Penney KL; Platz EA; Pollak MN; Roobol MJ; Schaefer CA; Schenk JM; Stattin P; Tamakoshi A; Thysell E; Tsai CJ; Touvier M; Van Den Eeden SK; Weiderpass E; Weinstein SJ; Wilkens LR; Yeap BB; ; Allen NE; Key TJ; Travis RC
Int J Epidemiol; 2023 Feb; 52(1):71-86. PubMed ID: 35726641
[TBL] [Abstract][Full Text] [Related]
3. Circulating insulin-like growth factor-I, total and free testosterone concentrations and prostate cancer risk in 200 000 men in UK Biobank.
Watts EL; Fensom GK; Smith Byrne K; Perez-Cornago A; Allen NE; Knuppel A; Gunter MJ; Holmes MV; Martin RM; Murphy N; Tsilidis KK; Yeap BB; Key TJ; Travis RC
Int J Cancer; 2021 May; 148(9):2274-2288. PubMed ID: 33252839
[TBL] [Abstract][Full Text] [Related]
4. Mendelian randomization analyses identified bioavailable testosterone mediates the effect of sex hormone-binding globulin on prostate cancer.
Wan B; Lu L; Lv C
Andrology; 2023 Sep; 11(6):1023-1030. PubMed ID: 36524281
[TBL] [Abstract][Full Text] [Related]
5. Circulating Levels of Testosterone, Sex Hormone Binding Globulin and Colorectal Cancer Risk: Observational and Mendelian Randomization Analyses.
Dimou N; Mori N; Harlid S; Harbs J; Martin RM; Smith-Byrne K; Papadimitriou N; Bishop DT; Casey G; Colorado-Yohar SM; Cotterchio M; Cross AJ; Marchand LL; Lin Y; Offit K; Onland-Moret NC; Peters U; Potter JD; Rohan TE; Weiderpass E; Gunter MJ; Murphy N
Cancer Epidemiol Biomarkers Prev; 2021 Jul; 30(7):1336-1348. PubMed ID: 33879453
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of sex hormone levels and risk of prostate cancer.
Gann PH; Hennekens CH; Ma J; Longcope C; Stampfer MJ
J Natl Cancer Inst; 1996 Aug; 88(16):1118-26. PubMed ID: 8757191
[TBL] [Abstract][Full Text] [Related]
7. Testosterone, sex hormone-binding globulin, insulin-like growth factor-1 and endometrial cancer risk: observational and Mendelian randomization analyses.
Mullee A; Dimou N; Allen N; O'Mara T; Gunter MJ; Murphy N
Br J Cancer; 2021 Oct; 125(9):1308-1317. PubMed ID: 34363033
[TBL] [Abstract][Full Text] [Related]
8. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era.
Platz EA; Leitzmann MF; Rifai N; Kantoff PW; Chen YC; Stampfer MJ; Willett WC; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1262-9. PubMed ID: 15894683
[TBL] [Abstract][Full Text] [Related]
9. Association of genetically determined chronotype with circulating testosterone: a Mendelian randomization study.
Ichikawa T; Kobayashi T; Hachiya T; Ikehata Y; Isotani S; Ide H; Horie S
Front Endocrinol (Lausanne); 2024; 15():1264410. PubMed ID: 38737549
[TBL] [Abstract][Full Text] [Related]
10. Prospective analyses of testosterone and sex hormone-binding globulin with the risk of 19 types of cancer in men and postmenopausal women in UK Biobank.
Watts EL; Perez-Cornago A; Knuppel A; Tsilidis KK; Key TJ; Travis RC
Int J Cancer; 2021 Aug; 149(3):573-584. PubMed ID: 33720423
[TBL] [Abstract][Full Text] [Related]
11. Causal effect of sex hormone-binding globulin and testosterone on coronary heart disease: A multivariable and network Mendelian randomization analysis.
Li Y; Si S; Hou L; Yuan T; Chen X; Liu C; Li W; Li H; Liu Y; Xue F
Int J Cardiol; 2021 Sep; 339():179-184. PubMed ID: 34181993
[TBL] [Abstract][Full Text] [Related]
12. Genetically predicted sex hormone levels and health outcomes: phenome-wide Mendelian randomization investigation.
Yuan S; Wang L; Sun J; Yu L; Zhou X; Yang J; Zhu Y; Gill D; Burgess S; Denny JC; Larsson SC; Theodoratou E; Li X
Int J Epidemiol; 2022 Dec; 51(6):1931-1942. PubMed ID: 35218343
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for prostate cancer: An umbrella review of prospective observational studies and mendelian randomization analyses.
Cui H; Zhang W; Zhang L; Qu Y; Xu Z; Tan Z; Yan P; Tang M; Yang C; Wang Y; Chen L; Xiao C; Zou Y; Liu Y; Zhang L; Yang Y; Yao Y; Li J; Liu Z; Yang C; Jiang X; Zhang B
PLoS Med; 2024 Mar; 21(3):e1004362. PubMed ID: 38489391
[TBL] [Abstract][Full Text] [Related]
14. Plasma testosterone and sex hormone-binding globulin concentrations and the risk of prostate cancer among Japanese men: a nested case-control study.
Sawada N; Iwasaki M; Inoue M; Sasazuki S; Yamaji T; Shimazu T; Tsugane S;
Cancer Sci; 2010 Dec; 101(12):2652-7. PubMed ID: 20942896
[TBL] [Abstract][Full Text] [Related]
15. Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study.
Fang S; Yarmolinsky J; Gill D; Bull CJ; Perks CM; ; Davey Smith G; Gaunt TR; Richardson TG
PLoS Med; 2023 Jan; 20(1):e1003988. PubMed ID: 36595504
[TBL] [Abstract][Full Text] [Related]
16. Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies.
Watts EL; Appleby PN; Perez-Cornago A; Bueno-de-Mesquita HB; Chan JM; Chen C; Cohn BA; Cook MB; Flicker L; Freedman ND; Giles GG; Giovannucci E; Gislefoss RE; Hankey GJ; Kaaks R; Knekt P; Kolonel LN; Kubo T; Le Marchand L; Luben RN; Luostarinen T; Männistö S; Metter EJ; Mikami K; Milne RL; Ozasa K; Platz EA; Quirós JR; Rissanen H; Sawada N; Stampfer M; Stanczyk FZ; Stattin P; Tamakoshi A; Tangen CM; Thompson IM; Tsilidis KK; Tsugane S; Ursin G; Vatten L; Weiss NS; Yeap BB; Allen NE; Key TJ; Travis RC
Eur Urol; 2018 Nov; 74(5):585-594. PubMed ID: 30077399
[TBL] [Abstract][Full Text] [Related]
17. Sex-specific Associations of Sex Hormone Binding Globulin with CKD and Kidney Function: A Univariable and Multivariable Mendelian Randomization Study in the UK Biobank.
Zhao JV; Schooling CM
J Am Soc Nephrol; 2021 Mar; 32(3):686-694. PubMed ID: 33318152
[TBL] [Abstract][Full Text] [Related]
18. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.
Yarmolinsky J; Bouras E; Constantinescu A; Burrows K; Bull CJ; Vincent EE; Martin RM; Dimopoulou O; Lewis SJ; Moreno V; Vujkovic M; Chang KM; Voight BF; Tsao PS; Gunter MJ; Hampe J; Pellatt AJ; Pharoah PDP; Schoen RE; Gallinger S; Jenkins MA; Pai RK; ; ; Gill D; Tsilidis KK
Diabetologia; 2023 Aug; 66(8):1481-1500. PubMed ID: 37171501
[TBL] [Abstract][Full Text] [Related]
19. Identifying molecular mediators of the relationship between body mass index and endometrial cancer risk: a Mendelian randomization analysis.
Hazelwood E; Sanderson E; Tan VY; Ruth KS; Frayling TM; Dimou N; Gunter MJ; Dossus L; Newton C; Ryan N; Pournaras DJ; O'Mara TA; Davey Smith G; Martin RM; Yarmolinsky J
BMC Med; 2022 Apr; 20(1):125. PubMed ID: 35436960
[TBL] [Abstract][Full Text] [Related]
20. Drug-target Mendelian randomization revealed a significant association of genetically proxied metformin effects with increased prostate cancer risk.
Sun X; Ping J; Guo X; Long J; Cai Q; Shu XO; Shu X
Mol Carcinog; 2024 May; 63(5):849-858. PubMed ID: 38517045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
